Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 4/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27754710 | 0.84 | POLB (0.38) | POLBAPEX1ACHEBCHEHTT | |
| SCHEMBL27961191 | 0.80 | GAA (0.38) | POLBAPEX1ACHEBCHEGAA | |
| SCHEMBL27572847 | 0.80 | SMARCA2 (0.40) | ACHEBCHEGAAKDM4EALDH1A1 | |
| SCHEMBL28030170 | 0.78 | ALDH1A1 (0.41) | ACHEBCHEALDH1A1KMT2ALMNA | |
| SCHEMBL27485356 | 0.77 | TP53 (0.36) | POLBAPEX1ACHEBCHEHTT | |
| SCHEMBL29287840 | 0.76 | KMT2A (0.40) | ACHEBCHEALDH1A1KMT2AHTT | |
| SCHEMBL29185989 | 0.76 | ELANE (0.51) | ALDH1A1KMT2AMAPT | |
| SCHEMBL6982295 | 0.76 | S1PR2 (0.44) | S1PR2POLBACHEBCHEKDM4E | |
| SCHEMBL28872846 | 0.75 | ACHE (0.36) | POLBAPEX1ACHEBCHEKDM4E | |
| SCHEMBL11798709 | 0.75 | FAAH (0.49) | POLBBCHEKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673891-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2394999-B1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2014-01-29 | — | — | EP | disclosed |
| US-8586591-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | NIPPON SHINYAKU CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
| EP-2394999-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | MC2R, AGTR2, AGTR1 | S1PR2 880/4885POLB 3313/4885APEX1 3996/4885 |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | MC2R, CNR1, NPY2R | S1PR2 900/4885POLB 3595/4885APEX1 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.